Registration and application of raw materials
We are engaged in the registration and application of international chemical apis and pharmaceutical excipients in China, and the general agent in the Chinese market. Our business partners cover Europe, America, India and other regions.
Intermediate import and export trade
We are engaged in the purchase and sales of pharmaceutical intermediates.
Provide diversified business
We are provide professional consulting and intermediary services for domestic enterprises in terms of internationalization, overseas registration of products, international GMP certification, and searching for overseas market partners.
ABOUT US

Our company is specialized in the registration and application of international chemical raw materials, pharmaceutical excipients, and finished preparations in China, as well as the general agency, marketing, and investment promotion in the Chinese market. At the same time, it also carries out the sales business of pharmaceutical intermediates, reference preparations, and impurity reference substances. The company is committed to supporting high-quality, reasonably priced, and guaranteed supply products for Chinese pharmaceutical enterprises, helping customers improve their product quality and market competitiveness, achieving long-term cooperation, mutual benefit, and win-win results, and contributing to improving the overall level of the Chinese pharmaceutical industry.
Our product advantage
We are committed to providing high-quality products and services to our customers. Quality is our soul. At the same time be sensitive to customer needs and strive to exceed their expectations.

Quality first
High quality standards, meet the requirements of the latest national pharmacopoeia.

Supply guarantee
The factory's production capacity can fully ensure that the customer's supply needs are met.

Production environment
Comply with on-site audits and future higher standard GMP requirements for hardware conditions.
Product Center
Advanced technology to provide customers with excellent products
Please call: 0086-0769-22777020
News Information
-
为贯彻落实中共中央办公厅、国务院办公厅《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》(厅字〔2017〕42号)与《国务院关于取消一批行政许可事项的决定》
-
根据《国家药监局关于实施有关事宜的公告》(2020年第46号),为推进相关配套规范性文件、技术指导原则起草制定工作
-
根据《国家药监局关于实施〈药品注册管理办法〉有关事宜的公告》(2020年第46号),为推进相关配套规范性文件、技术指导原则起草制定工作
-
按照《国家药监局关于实施药品注册申请电子申报的公告》(2022年第110号)要求,自2023年1月1日起